Abstract 433P
Background
Previous researches have reported on the protective effect of aspirin on different types of cancers. However, evidence from observational studies can be biased by multiple confounding factors. Also, it remains unclear whether aspirin use is casually related to a decreased cancer risk. Consequently, we conducted Mendelian randomization analyses, using single nucleotide polymorphisms (SNPs) as instrumental variables to investigate the casual effect of aspirin on different types of cancers.
Methods
Mendelian randomization analyses were conducted using pooled statistics from corresponding researches and several large-scale consortia. Inverse-variance weighted, MR-Egger and weighted median methods were utilized to evaluate the possible causal relationship between aspirin and the observed reduction in cancer risk. Results were shown by odds ratios (OR) and their corresponding 95% CIs. Analyses were conducted using the package “TwoSampleMR” in R.
Results
A total of 19 cancers corresponding to 344,392 cases and 5,424,758 controls were included in the final analysis. In contrast to the lower risk for various cancer types reported in conventional observational studies, our MR results only showed a decreased risk in lung cancer [odds ratio (OR) 0.0418; 95% confidence interval (CI) 0.0031-0.5638; P=0.0168] and squamous cell lung cancer [OR=0.002; 95% CI 1.2145×10-5-0.3009; P=0.0153]. Insignificant results were observed in other types of cancers including lung adenocarcinoma, breast cancer, ovarian cancer, colon cancer, kidney cancer, liver cancer, esophageal cancer, oral cancer, pancreas cancer, rectal cancer, malignant melanoma, non-melanoma skin cancer, Hodgkin’s lymphoma as well as non-Hodgkin’s lymphoma.
Conclusions
The potential effect of aspirin in cancer prevention still needs to be interpreted with cautions and aspirin is still too early to be recommended as a universal chemoprotective agent for primary cancer prevention. Further randomized controlled trials with a more rigorous design are warranted in the future.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
359P - The role of adjuvant targeted therapy for postoperative EGFR mutant non-small cell lung cancer: A network meta-analysis
Presenter: Guang Ling Jie
Session: e-Poster Display Session
360P - Number of lymph nodes examined was not an independent risk factor for the survival of patients with stage IA1-2 lung adenocarcinoma undergoing sublobar resection
Presenter: Zhenbin Qiu
Session: e-Poster Display Session
361P - Radiomic model predicting radiological response after thoracic stereotactic body radiotherapy regardless of tumor histology and staging
Presenter: Ben Man Fei Cheung
Session: e-Poster Display Session
362P - Integrative and comparative genomic analysis and immune microenvironment features of lung cancer patients with tuberculosis
Presenter: Xiaoling Xu
Session: e-Poster Display Session
363P - Genetic predisposition for pre-invasive lung adenocarcinoma manifesting as ground-glass nodules with family history of lung cancer
Presenter: Rui Fu
Session: e-Poster Display Session
364P - A deep learning model for the classification of lung cancer
Presenter: Gouji Toyokawa
Session: e-Poster Display Session
365P - Utilization of on-site pathology evaluation for lung cancer diagnosis in the Philippines’ National University Hospital
Presenter: Rich Ericson King
Session: e-Poster Display Session
367P - Detection of epidermal growth factor receptor mutations (EGFR-mut) from cell-free DNA in pleural effusion (PE-DNA) of patients with non-small cell lung cancer (NSCLC)
Presenter: Kirsty Lee
Session: e-Poster Display Session
368P - Real-world characteristics, treatment, and outcomes of stage III non-small cell lung cancer in Japan: SOLUTION study
Presenter: Haruyasu Murakami
Session: e-Poster Display Session
369P - The surgical perspective in neoadjuvant immunotherapy for resectable non-small cell lung cancer
Presenter: Long Jiang
Session: e-Poster Display Session